Alemtuzumab in Chronic Lymphocytic Leukemiaanglais
Version: 2 ID: 6-16 Version 2 fév 2014
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Adult patients with CLL.
- Is alemtuzumab a beneficial treatment option, with respect to outcomes such as survival, response rate, response duration, time-to-progression, and quality of life, for patients with Bcell chronic lymphocytic leukemia (CLL)?
- What toxicities are associated with the use of alemtuzumab?
- Which patients are more likely, or less likely, to benefit from treatment with alemtuzumab?
Full Report (PDF) (1.27 Mo)